Skip to main content

Advertisement

SpringerLink
Log in

Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Many studies have reported the role of COMT Val158Met with breast cancer risk, but the results remained controversial. In addition, previous meta-analysis on COMT Val158Met showed conflicting results. Hence, we performed a meta-analysis to investigate the association between breast cancer and COMT Val158Met (30,199 cases and 38,922 controls) in different inheritance models. When all the eligible studies were pooled into this meta-analysis, there was no evidence of significant association between breast cancer risk and COMT Val158Met polymorphism in any genetic model (dominant model: odds ratio [OR] = 0.99, 95% confidence interval [CI] = 0.94–1.04, P value of heterogeneity test [P h] = 0.009, I 2 = 36.9%; recessive model: OR = 0.97, 95% CI = 0.92–1.02, P h = 0.044, I 2 = 28.6%; additive model: OR = 0.98, 95% CI = 0.91–1.05, P h = 0.004, I 2 = 40.4%). However, significant between-study heterogeneity was detected in any genetic model. Hence, we performed the stratified analysis according to ethnicity, source of controls, menopausal status, and family history. In the stratified analysis by ethnicity significantly decreased breast cancer risk was observed in Caucasian population (recessive model: OR = 0.96, 95% CI = 0.92–1.00, P h = 0.419, I 2 = 3.1%). In conclusion, this meta-analysis indicates that COMT Val158Met polymorphism may be associated with decreased breast cancer risk in Caucasian population. However, a study with the larger sample size is needed to further evaluated gene-environment interaction on COMT Val158Met polymorphisms and breast cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA (1998) Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130–1136

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  3. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. BMJ 321:624–628

    Article  PubMed  CAS  Google Scholar 

  4. Sim X, Ali RA, Wedren S, Goh DL, Tan CS, Reilly M (2006) Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968–2002. BMC Cancer 6:261

    Article  PubMed  Google Scholar 

  5. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225–242

    Article  PubMed  Google Scholar 

  6. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854

    PubMed  CAS  Google Scholar 

  7. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 7:419–424

    Google Scholar 

  8. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF (2001) Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61:6716–6722

    PubMed  CAS  Google Scholar 

  9. Goodman JE, Jensen LT, He P, Yager JD (2002) Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 12:517–528

    Article  PubMed  CAS  Google Scholar 

  10. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493–5497

    PubMed  CAS  Google Scholar 

  11. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ, Bell DA (1998) Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 19:1943–1947

    Article  PubMed  CAS  Google Scholar 

  12. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB (1998) Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58:2107–2110

    PubMed  CAS  Google Scholar 

  13. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59:4870–4875

    PubMed  CAS  Google Scholar 

  14. Bergman-Jungestrom M, Wingren S (2001) Catechol-O-methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer 85:859–862

    Article  PubMed  CAS  Google Scholar 

  15. Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD (2001) COMT genotype micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 22:1661–1665

    Article  PubMed  CAS  Google Scholar 

  16. Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Oya H, Obata Y (2001) Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol 6:13–18

    Article  PubMed  CAS  Google Scholar 

  17. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A (2001) Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:635–640

    PubMed  CAS  Google Scholar 

  18. Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, Ahn SH, Noh DY, Choe KJ, Jang IJ, Shin SG, Strickland PT, Hirvonen A, Kang D (2001) Relationship between the Val108/158Met polymorphism of catechol-O-methyl transferase and breast cancer. Pharmacogenetics 11:279–286

    Article  PubMed  CAS  Google Scholar 

  19. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE (2002) Cytochrome P450 CYP1B1 and catechol-O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol 76:643–649

    Article  PubMed  CAS  Google Scholar 

  20. Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, Mac-Murray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97:2160–2170

    Article  PubMed  CAS  Google Scholar 

  21. Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, Lin DX (2003) Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi 25:453–456

    PubMed  CAS  Google Scholar 

  22. Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I, Magnusson C (2003) Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 24:681–687

    Article  PubMed  CAS  Google Scholar 

  23. Wu AH, Tseng CC, Van Den Berg D, Yu MC (2003) Tea intake, COMT genotype, and breast cancer in Asian–American women. Cancer Res 63:7526–7529

    PubMed  CAS  Google Scholar 

  24. Ahsan H, Chen Y, Whittemore AS, Kibriya MG, Gurvich I, Senie RT, Santella RM (2004) A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat 85:121–131

    Article  PubMed  CAS  Google Scholar 

  25. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96:936–945

    Article  PubMed  CAS  Google Scholar 

  26. Sazci A, Ergul E, Utkan NZ, Canturk NZ, Kaya G (2004) Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients. Toxicology 204:197–202

    Article  PubMed  CAS  Google Scholar 

  27. Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, Wu PE, Shen CY (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113:345–353

    Article  PubMed  CAS  Google Scholar 

  28. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14:1998–2003

    Article  PubMed  CAS  Google Scholar 

  29. Lin WY, Chou YC, Wu MH, Jeng YL, Huang HB, You SL, Chu TY, Chen CJ, Sun CA (2005) Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: a nested case–control study in Taiwan. Cancer Detect Prev 29:427–432

    Article  PubMed  CAS  Google Scholar 

  30. Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, Yu JC, You SL, Chen CJ, Sun CA (2005) Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev 14:257–261

    Article  PubMed  Google Scholar 

  31. Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 93:261–270

    Article  PubMed  CAS  Google Scholar 

  32. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, Gao YT, Zheng W (2005) Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 14:329–335

    Article  PubMed  CAS  Google Scholar 

  33. Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W (2006) Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast J 15:754–761

    Article  Google Scholar 

  34. Gallicchio L, Berndt SI, McSorley MA, Newschaffer CJ, Thuita LW, Argani P, Hoffman SC, Helzlsouer KJ (2006) Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 6:173

    Article  PubMed  Google Scholar 

  35. Gaudet MM, Chanock S, Lissowska J, Berndt SI, Peplonska B, Brinton LA, Welch R, Yeager M, Bardin-Mikolajczak A, Garcia-Closas M (2006) Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk. Cancer Res 66:9781–9785

    Article  PubMed  CAS  Google Scholar 

  36. Gaudet MM, Bensen JT, Schroeder J, Olshan AF, Terry MB, Eng SM, Teitelbaum SL, Britton JA, Lehman TA, Neugut AI, Ambrosone CB, Santella RM, Gammonn MD (2006) Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York. Breast Cancer Res Treat 99:235–240

    Article  PubMed  CAS  Google Scholar 

  37. Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H (2006) SNP–SNP interactions in breast cancer susceptibility. BMC Cancer 6:114

    Article  PubMed  Google Scholar 

  38. Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM (2006) Prevalence of Val108/158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer. Zhonghua Wai Ke Za Zhi 44:1310–1313

    PubMed  Google Scholar 

  39. Akisik E, Dalay N (2007) Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer. J Clin Lab Anal 21:97–102

    Article  PubMed  CAS  Google Scholar 

  40. Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, De-Freese DC, Gramling BA, Shimasaki CD, Jupe ER (2007) Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 109:1940–1948

    Article  PubMed  CAS  Google Scholar 

  41. Takata Y, Maskarinec G, Le Marchand L (2007) Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the multiethnic cohort. BMC Cancer 7:30

    Article  PubMed  Google Scholar 

  42. Pharoah PD, Tyrer J, Dunning AM et al (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42

    Article  PubMed  Google Scholar 

  43. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009) A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 113:585–594

    Article  PubMed  CAS  Google Scholar 

  44. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H, Ozcelik H (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8:6

    Article  PubMed  Google Scholar 

  45. Jakubowska A, Gronwald J, Menkiszak J, Gor’ski B, Huzarski T, Byrski T, Tołoczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubin’ski J, Scott RJ, Hamann U (2009) BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat 119:201–211

    Article  PubMed  Google Scholar 

  46. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 119:463–474

    Article  Google Scholar 

  47. Reding KW, Weiss NS, Chen C, Li CI, Carlson CS, Wilkerson HW, Farin FM, Thummel KE, Daling JR, Malone KE (2009) Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18:1461–1467

    Article  PubMed  CAS  Google Scholar 

  48. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125:837–843

    Article  PubMed  CAS  Google Scholar 

  49. Peterson NB, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Huang Y, Chanock SJ, Haines JL, Egan KM (2010) Association of COMT haplotypes and breast cancer risk in caucasian women. Association of COMT haplotypes and breast cancer risk in caucasian women. Anticancer Res 30:217–220

    PubMed  CAS  Google Scholar 

  50. Wang Q, Wang YP, Li JY, Yuan P, Yang F, Li H (2010) Polymorphic catechol-O-methyltransferase gene, soy isoflavone intake and breast cancer in postmenopausal women: a case–control study. Chin J Cancer 29:683–688

    PubMed  Google Scholar 

  51. Delort L, Satih S, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ (2010) Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms. Nutr Cancer 62:243–251

    Article  PubMed  CAS  Google Scholar 

  52. Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R (2010) Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Invest 28:304–311

    Article  PubMed  CAS  Google Scholar 

  53. Cribb AE, Joy Knight M, Guernsey J, Dryer D, Hender K, Shawwa A, Tesch M, Saleh TM (2011) CYP17, catechol-o-methyltransferase, and glutathione transferase M1 genetic polymorphisms, lifestyle factors, and breast cancer risk in women on Prince Edward Island. Breast J 17:24–31

    Article  PubMed  Google Scholar 

  54. Cerne JZ, Pohar-Perme M, Novakovic S, Frkovic-Grazio S, Stegel V, Gersak K (2011) Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. J Gynecol Oncol 22:110–119

    Article  PubMed  CAS  Google Scholar 

  55. Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, Shao ZM (2007) A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol 133:969–978

    Article  PubMed  CAS  Google Scholar 

  56. Ding HX, Fu YY, Chen WX, Wang ZW (2010) COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case–control studies. Breast Cancer Res Treat 123:265–270

    Article  PubMed  CAS  Google Scholar 

  57. Mao C, Wang XW, Qiu LX, Liao RY, Ding H, Chen Q (2010) Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat 121:719–725

    Article  PubMed  CAS  Google Scholar 

  58. Davey SG, Egger M (1997) Meta-analyses of randomized controlled trials. Lancet 350:1182

    Google Scholar 

  59. Ioannidis JP, Boffetta P, Little J et al (2008) Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37:120–132

    Article  PubMed  Google Scholar 

  60. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Natl Cancer Inst 22:719–778

    CAS  Google Scholar 

  61. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  62. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  PubMed  CAS  Google Scholar 

  63. Egger M, Smith DG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  64. Weisz J (1994) Biogenesis of catecholestrogens: a mechanism for metabolic activation of estrogens. Polycycl Aromat Compd 6:241–251

    Article  CAS  Google Scholar 

  65. Liehr JG (1997) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6:3–10

    Article  PubMed  CAS  Google Scholar 

  66. Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1–27

    Article  PubMed  Google Scholar 

  67. Yager D, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203–232

    Article  PubMed  CAS  Google Scholar 

  68. Butterworth NJ, Dragunow M (1996) Medial septal cholinergic neurons express c-Jun but do not undergo DNA fragmentation after fornix-fimbria transections. Brain Res Mol Brain Res 43:1–12

    Article  PubMed  CAS  Google Scholar 

  69. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996) Human catechol-o-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:25–243

    Article  Google Scholar 

  70. Scanlon PD, Raymond FA, Weinshilboum RM (1979) Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 5:63–65

    Article  Google Scholar 

  71. Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Xiao-Feng He, Wu Wei, Ying Zhang, and Xiang-Hua Ye contributed equally to this study and should be considered as co-first authors.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Information Section, Peace Hospital of Changzhi Medical College, Changzhi, 046000, China

    Xiao-Feng He & Shao-Xia Li

  2. Department of Hematology, Peace Hospital of Changzhi Medical College, Changzhi, 046000, China

    Wu Wei

  3. Department of Biological Chemistry, Changzhi Medical College, Changzhi, 046000, China

    Jiao Su

  4. College of Pharmacy, Jinan University, Guangzhou, 510632, China

    Ying Zhang

  5. Department of Radiotherapy, First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, 310003, China

    Xiang-Hua Ye

  6. Department of Neurosurgery, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, China

    Yi Liu

  7. Biomedical Imaging Research Center, University of Fukui, Eiheiji, Fukui, 910-1193, Japan

    Wei Wang

Authors
  1. Xiao-Feng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wu Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shao-Xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiao Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiang-Hua Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Feng He.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, XF., Wei, W., Li, SX. et al. Association between the COMT Val158Met polymorphism and breast cancer risk: a meta-analysis of 30,199 cases and 38,922 controls. Mol Biol Rep 39, 6811–6823 (2012). https://doi.org/10.1007/s11033-012-1506-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1506-2

Keywords

Search

Navigation